SCM
LAB icon

Scopia Capital Management’s Standard BioTools LAB Stock Holding History

Scopia Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,508,120
Closed -$16.3M – 44
2015
Q4 		$16.3M Buy
1,508,120
+200,330
+15% +$1.97M 0.32% 30
2015
Q3 		$10.6M Buy
+1,307,790
New +$20.6M 0.23% 34

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RFC
Russell Frank Company Seattle, Washington $56.9B AUM 2.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Scopia Capital Management's LAB Position: Q1 2016 in Review

Scopia Capital Management sold out of Standard BioTools (LAB) in Q1 2016, closing a stake of 1,508,120 shares — an estimated $16.3M sold.

Scopia Capital Management first reported a position in LAB in Q3 2015 and held it in 2 quarters. The position peaked at $16.3M in Q4 2015. 100 funds tracked by Wall St. Rank hold LAB as of Q1 2016.

  • Scopia Capital Management reported no remaining Standard BioTools position as of Q1 2016 after selling out during the quarter.
  • Scopia Capital Management sold 1,508,120 Standard BioTools shares in Q1 2016, an estimated $16.3M.
  • Scopia Capital Management first reported a position in Standard BioTools in Q3 2015 and held it in 2 quarters.
  • Scopia Capital Management's Standard BioTools position peaked at $16.3M in Q4 2015.
  • 100 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2016.

Based on Scopia Capital Management's 13F filing for Q1 2016, filed 16 May 2016.